

سامية محمد مصطفى



شبكة المعلومات الجامعية

بسم الله الرحمن الرحيم



سامية محمد مصطفى



شبكة المعلومات الجامعية



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



سامية محمد مصطفى



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



سامية محمد مصطفى



شبكة المعلومات الجامعية



بعض الوثائق الأصلية تالفة



سامية محمد مصطفى



شبكة المعلومات الجامعية



بالرسالة صفحات لم ترد بالأصل



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

B

١٢٧-٥

EVALUATION OF CYTOKERATIN 18 IN THE DIAGNOSIS OF CANCER BREAST

Thesis

**Submitted to the Faculty of Medicine
University of Alexandria
In partial fulfilment of the
Requirement of the degree of**

MASTER OF CLINICAL PATHOLOGY

By

**DOAA IBRAHIM HASHAD
MBBCH (ALEX)**

**Faculty of Medicine
University of Alexandria**

2001

SUPERVISORS

Prof.Dr. MONA SOBHI SEDRAK

Professor of Clinical Pathology
Faculty of Medicine
University of Alexandria

Dr. DALAL MOHAMMED NASR ELDIN ELKAFFASH

Lecturer of Clinical Pathology
Faculty of Medicine
University of Alexandria

Dr. HOSSAM ELDIN ABOUL FETOUH HASSAB

Assistant Professor of Surgery
Faculty of Medicine
University of Alexandria

Co-worker

Dr. SUZAN FAROUK HELAL

Assistant Professor of Pathology
Faculty of Medicine
University of Alexandria

*TO MY BELOVED PARENTS,
MY CARING HUSBAND &
SARA.*

ACKNOWLEDGEMENT

I am greatly indebted and grateful to Prof. Dr. Mona Sobhi Sedrak, professor of clinical pathology, for her constant support, valuable suggestions and helpful advice.

No words can express my thanks and gratitude to Dr. Dalal Mohammed Nasr Eldin Elkaffash, lecturer of clinical pathology, for her meticulous supervision and revision of the whole text.

My deepest thanks and appreciation to Dr. Hossam Eldin Aboul Fetouh Hassab, assistant professor of surgery for his kind encouragement and helpful advice.

I would like to express my gratitude and deep appreciation to Dr. Suzan Farouk Helal, assistant professor of pathology, for her kind encouragement side by side with her valuable assistance and helpful advice.

CONTENTS

Chapter	Page
I. INTRODUCTION	1
• Epidemiology of breast cancer.	1
• Diseases of the breast.	2
• Breast cancer.	3
• Tumour markers.	14
• Breast cancer markers.	20
• CA 15-3.	25
• Cytokeratin 18.	28
II. AIM OF THE WORK.	34
III. MATERIAL	35
IV. METHODS.	37
V. RESULTS.	54
VI. DISSCUSION.	109
VII. SUMMARY.	120
VIII. CONCLUSIONS.	123
XI. REFERENCES.	124
-PROTOCOL.	
- ARABIC SUMMARY.	

LIST OF ABBREVIATIONS

A°: angstrom.

AJCC: American joint committee on cancer.

ALP: Alkaline phosphatase.

ASCO: American society of clinical oncology.

CBC: Complete blood picture.

CEA: Carcinoembryonic antigen

C-terminal: Carboxy terminal.

DNA: Deoxy nucleic acid.

EDTA: Ethylene diamine tetrachloroacetic acid.

ELISA: Enzyme linked immunosorbant assay.

ESR: Erythrocyte sedimentation rate.

F: Fisher's exact test.

FBG: Fasting blood glucose.

GIT: Gastrointestinal tract.

Hct: Haematocrit value.

HRP: horse raddish peroxidase.

IF: Intermediate filaments.

IFP_s: Intermediate filaments proteins.

Ig: Immunoglobulin.

KA: King Armstrong unit.

M: Molar.

Mab: Monoclonal antibody.

MCH: Mean corpuscular haemoglobin.

MCHC: Mean corpuscular haemoglobin concentration.

MCV: Mean corpuscular volume.

MIT: Methyl isothiazolone.

n: Number of analyzed variables.

NPV: Negative predictive value.

P: probability.

Plat_s: Platelets.

PH: Power of hydrogen.

PI: Isoelectric point.

PPV: positive predictive value.

q: Long arm of the chromosome.

RBC_s: Red blood cells.

RIA: Radioimmunoassay.

ROC: Receiver operating characteristic curve.

TMB: 3,3',5,5' tetra- methyl- benzidine.

TNM: Tumour-node-metastasis.

TPA: Tissue polypeptide antigen.

TPS: Tissue polypeptide specific antigen.

TRIS: Tris (hydroxy methyl) aminomethane buffer.

N-terminal: Amino-acid terminal.

S phase: Phase of synthesis.

WBC_s: White blood cells.

LIST OF TABLES

Table NO.		Page
I	Age distribution of the studied groups.	54
II	Haematological profile of the study samples.	64
III	Biochemical profile of the studied groups.	69
IV	Mean value of CA 15-3 marker (U/ml) in the studied groups.	70
V	Mean level of cytokeratin 18 marker (U/L) in the studied groups.	72
VI	Mean values of CA 15-3 (U/ml) and cytokeratin 18 markers (U/L) in early and advanced breast cancer subjects.	76
VII	Distribution of the studied groups according to the positivity rate (%) of markers.	82
VIII	Distribution of early and advanced breast subjects according to the positivity rate.	83
IX	2 x 2 classification of 140 subjects by histopathological diagnosis of breast cancer as a gold standard and a cut-off point of 30 U/ml for CA 15-3 marker.	85
X	2 x 2 classification of 140 subjects by histopathological diagnosis of breast cancer as a gold standard and a cut-off point of 80 U/L for cytokeratin 18 marker.	87